Actualités

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic

DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HRB, DVA and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 4th, 2026.

DaVita’s latest analyst update keeps the model fair value anchored at US$193.71 per share, signaling a steady headline price target in the newest run of assumptions. Behind that number, recent research has focused on how changes in discount rates and company specific risk views are shaping both higher targets and ongoing caution around the stock. As you read on, you will see how this evolving narrative fits together and what it can mean for tracking DaVita from here. Analyst Price Targets...

DVA raises guidance on stronger dialysis volumes and reimbursement gains, but rising patient-care and technology costs could squeeze margins.

HRB, DVA and LCUT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 2nd, 2026.

DaVita is highlighted as Zacks Bull of the Day, while Arcosa faces pressure from weakening earnings revisions.

DaVita has soared over 70% in 2026 to new highs. The dialysis services giant is projected to double its EPS between 2023 and 2027. Even though it's up 3,000% in the past 25 years, DVA trades at value stock levels.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

CNC, SANM and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 26, 2026.

Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

LCUT, GECC, ARKO, PBI and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2026.

DaVita, Integra, Braskem and LyondellBasell screen as attractive GARP stocks, combining growth potential with discounted PEG ratios.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

In recent days, DaVita announced its 2030 Community Care commitments, highlighting goals to empower 150,000 patients through kidney education, support 40,000 transplants, and maintain 100% renewable energy use to bolster care continuity. At the same time, DaVita’s recognition of 57 DAISY Award–winning nephrology nurses and a strong value rating from analysts underscore how workforce investment and perceived valuation strength are shaping perceptions of the company’s long-term resilience...

DaVita (NYSE:DVA) recognized 57 nephrology nurses with the 2026 DAISY Award for Extraordinary Nurses. The awards highlight nursing excellence and patient care within the company's kidney care operations. This recognition focuses on frontline caregivers as a core part of DaVita's service delivery model. For investors watching NYSE:DVA, this update fits within the context of a business built around chronic kidney care and long-term patient relationships. In a sector where staffing remains...

MUSA, DVA, MCHP and CVE are near 52-week highs as earnings growth, cash flow strength and expansion plans fuel momentum.

Nomad Foods is a leading European frozen foods producer with a broad portfolio of well-known brands sold across major supermarket chains.

Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, MCHP and CVE are seeing price strength, and the momentum is likely to continue.

GPRE, DVA and SNX made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 21, 2026.

DVA, TAL, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 21, 2026.

DaVita (NYSE:DVA) has announced its 2030 Community Care commitments, outlining new long-term ESG goals. The plan focuses on patient outcomes, workforce development, and environmental sustainability. The commitments are framed as a multiyear roadmap through 2030 for the company’s community and ESG priorities. DaVita operates as a kidney care provider, so any shift in how it approaches patient outcomes and workforce development can matter for how the core business functions over time. ESG has...

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

UVE, LCUT and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 19, 2026.

DVA, PBI, and LCUT it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 19, 2026.

DaVita, Antero Resources, PBF Energy and Popular are highlighted as low-PEG value stocks with growth potential.

Low-PEG stocks like DaVita, AR, PBF and Popular stand out as value plays with strong growth potential and discounted valuations.

As it gets easier to create artificial-intelligence agents with platforms like Anthropic’s Claude Cowork , some businesses are dealing with ‘AI agent sprawl.’

DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvement